Ipsen SA has shown itself to be a canny dealmaker over the past few years and its negotiating skills have been shown again with the sale of a priority review voucher (PRV) at well above market rate.
The French drugmaker has revealed that it has agreed to sell its rare pediatric disease PRV to "a large global...
Welcome to Scrip
Create an account to read this article
Already a subscriber?